Evaluation -- The Z-VAD-FMK Pros And also Negatives

In the gefitinib arm, 53 patients (79%) received platinum-based chemotherapy, and 14 patients (21%) received nonplatinum chemotherapy (gemcitabine plus vinorelbine [12 patients], pemetrexed [1 patient], or irinotecan [1 patient]) as second-line therapy. The distribution of SNPs http://www.selleckchem.com/products/ly2157299.html is also provided in Table 1. All variants were in Hardy-Weinberg equilibrium (P > .05). Among 158 patients, tumor ERCC1 expression and EGFR mutations were evaluable in 38 patients and 42 patients, respectively. ERCC1-positive tumors comprised 55% (n = 21). Among 42 evaluable tumors, EGFR mutations were identified in 23 (55%). Sixteen patients exhibited an in-frame deletion in exon 19, and 7 patients had the leucine-to-arginine substitution at amino acid 858 (L858R) point mutation in exon 21. No significant correlation was observed between ERCC1 expression and EGFR mutations. In addition, no significant correlation was observed between patients' clinical characteristics (e.g., age, performance status, disease stage, and sex) and genotypes, ERCC1 expression, or EGFR mutations (data not shown). The overall response to each treatment was compared within treatment arms according to genotype, ERCC1 expression, and EGFR mutations http://www.selleckchem.com/products/z-vad-fmk.html status. In the GP arm, a higher response rate (RR) was observed among patients who had ERCC1-negative tumors compared with patients who had ERCC1-positive tumors (88% vs 17%; P = .026). Patients who had the ERCC1 8092 adenine-adenine (AA) genotype also had a trend toward a higher RR compared with patients who had the cytosine-cytosine (CC) or CA genotypes (100% vs 46% vs 41%; P = .082; AA vs CC + CA; P = .043). In the gefitinib arm, a higher RR was observed for patients who had EGFR mutations compared with patients who had wild-type EGFR (89% vs 13%; P http://www.selleck.cn/products/XL184.html with EGFR mutations (87% vs 38%; P = .026) had a significantly higher RR to gefitinib compared with GP. In addition, patients with the ERCC1 8092CA (41% vs 64%; P = .05) and XRCC1 399Arg/Arg (54% vs 71%; P = .094) genotypes and those with ERCC1-positive tumors (54% vs 13%; P = .085) had a trend toward a higher RR to gefitinib compared with GP. Because the RR to each treatment was affected significantly by ERCC1 expression or EGFR mutations, the association with genotypes was examined. Patients with the XRCC1 399Arg/Arg genotype, which was associated with a higher RR to gefitinib, had more EGFR mutations than those with the Arg/Gln or Gln/Gln genotypes (82% vs 29% vs 0%; P = .001). Although it is believed that the SNPs examined here are related to DRC, no significant correlation with ERCC1 expression was observed.